Editorial: Put Robots In The C-Suite!
This article was originally published in Scrip
The pharma C-suite is beset by sickness. From exotic orphan conditions like Dys-shkreli-a (a dangerous propensity to drag the industry into disrepute that can be crippling for host companies) to pneumonia following intense scrutiny (Valeant's Pearson), the risks are many. Non-compete-itis saw off MannKind's new CEO before he'd even set foot in the corner office. Many companies watch millions of dollars bleeding uncontrollably out through their C-suites with no effective clotting agent available to staunch the flow.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.